Join
Live feed
·
PRReleasevia Quantisnow
Kodiak Sciences Inc logo

Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026

ByQuantisnow·Wall Street's wire, on your screen.
KOD· Kodiak Sciences Inc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KOD (Kodiak Sciences Inc) and more on Quantisnow.